Friday 22nd May 2020
World Family Doctor Day
Although World Family Doctor Day has now passed for this year (19th May) there is still time to view the messages from the WONAC Executive too all our members. WONCA Europe also posted a YouTube message and both can be viewed here
WONCA webinars relating to COVID-19
The series of WONCA webinars continues, and this week it’s the turn of Quality and Safety. For those who have been unable to attend the webinars they can all be viewed on YouTube or on Youku
In coming weeks sessions have been arranged for:
Sunday 24th May - Quality and Safety
Sunday 31st May (1000GMT) - Research
See the link in the title above or the banner at the foot of the page for how to register for the latest webinar.
WONCA Featured Doctor: Dr Nagwa Nashat Hegazy (Egypt)
One of this month’s featured doctors is Dr Nagwa from Egypt, a family doctor and medical educator. She works in a University setting, providing primary health care and teaching undergraduate and postgraduate medical students. She is also the inaugural Director of the Medical Education and Human Resources Development Center (MEHRDC) in the Faculty of Medicine, Menoufia University. In addition to all that, she is a writer for the Applied Knowledge Test, examiner in the OSCE and Scientific Board member of the Egyptian Family Medicine team of the MRCGP (INT). She is also an Egyptian Family Medicine Association (EFMA) executive board member.
Sponsored link: WONCA and myCME
WONCA invites you to participate in a live International Town Wall® with leading international experts on Atopic Dermatitis on Thursday, May 28 at 12:00 pm EDT / 4:00 pm GMT / 5:00 pm BST, in partnership with Haymarket Medical Education and myCME.
This free, live, one-hour, virtual continuing medical education (CME)/continuing education (CE) webcast, “Optimizing Management of Moderate to Severe Atopic Dermatitis:
Perspectives From Both Sides of the Pond” via a dynamic, interactive myCME Town Wall® forum. Earn 1.0 CME/CE Credits* and learn more about:
Incorporating into practice new findings on the immunopathogenesis of atopic dermatitis (AD)
Describing the mechanisms of action, efficacy, and safety of new and emerging targeted agents for the treatment of moderate to severe AD and relay this information to patients
Implementing individualized treatment plans for moderate to severe AD that consider disease severity, comorbidities, age, and quality of life in the context of shared decision-making and therapeutic patient education
Register here for free, here.
*AMA PRA Category 1 Credit™ is generally accepted as equivalent to EACCME credit in Europe, through a reciprocity agreement between the American Medical Association and the European Union of Medical Specialists (UEMS).